Home > News and Events > Press Releases > content
Ministry of Economic Affairs designates UBP an “innovative pharmaceutical company”

United BioPharma (UBP, 6471) was approved and designated as an “innovative pharmaceutical company” by the Ministry of Economic Affairs.

Under the Act for the Development of Biotech and New Pharmaceutical Industry, designated innovative pharmaceutical companies are offered tax relief preferences including “research and development talent training costs,” “investment from shareholders,” and “tax exemption in the year of designation for the technology stocks or stock option certificates that high-level professionals and technology investors received.”

About United BioPharma (6471)

Founded in October 2013, United BioPharm (UBP) was spun-off from its parent company, United Biomedical, Inc., Asia, to focus on its monoclonal antibody drugs business. UBP has established a strategic partnership with Taiwan conglomerate, Formosa Plastics Group and its Chang-Gung Memorial Hospital network. UBP possesses a comprehensive technology platform for antibody drug development and is focused on the R&D, manufacture, and global commercialization of innovative monoclonal antibodies and biosimilar antibodies with significant market potential. Driven by innovation and execution, UBP strives to provide effective therapeutics to address unmet medical needs, improve human health and contribute to Taiwan’s economic development.

For additional information about the company, please visit http://www.unitedbiopharma.com

Contact: Victor Sun, VP of Business Administration and Spokesperson
Tel: 886-3-668-4800 ext 808